Bioventus Inc.

NASDAQ:BVS

Medical - Devices

Healthcare
$10.62 +2.11%

+$0.18 today

Market cap
$727.20M
Beta
0.67
P/E (TTM)
20.6
EPS (TTM)
$0.42
52W Low $5.81High $11.25

Volume 0.70M

Average 0.56M

BVS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Bioventus Inc.NASDAQ: BVS

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables declines year over year

Q1 FY2026 accounts receivables of $7.32M fell 18.7% year over year, ahead of the -979.1% change in trailing-twelve-month accounts receivables. Sequentially, it rose 288.2% from the prior quarter. Over 3 fiscal years it compounded at -62.7% a year.

Context

  • Accounts receivables amounted to 0.2% of revenue in FY2025, down 1.7 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -18.7% holds above the trailing-twelve-month pace of -979.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$7.32M+288.2% QoQ
Last fiscal yearDec 2025
-$916K-91.4% YoY
LTMMar 2026
-$2.6M-979.1% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.7%——
1 year-91.4%——
3-year CAGR-62.7%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(916K) USD
Year-over-year change
+91.4%

Accounts Receivables vs competitors

How BVS compares with its peers on the latest reported figures

  • BVS's LTM Mar 2026 accounts receivables of $2.6M is the 8th largest of the 9 companies compared; the peer median is $1.65M.
  • Its year-over-year change of -979.1% is the lowest of 9, against a peer median of +141.0%.
  • Accounts receivables amounts to 0.5% of revenue for BVS, versus a peer median of 2.4%.
BVS Competitors Peer median
Accounts Receivables for BVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNNSmith & Nephew plcFY2025$175M +116.0%+19.3%2.8%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$16.97M +54.1%+136.4%3.3%
MDXGMiMedx Group, Inc.LTM Mar 2026$9.02M +240.7%+64.4%2.3%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$8.29M -169.0%-75.7%0.5%
OFIXOrthofix Medical Inc.LTM Mar 2026$5.26M +166.0%-38.3%0.6%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$4.81M -273.1%—4.1%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$2.97M +199.2%-46.9%2.4%
BVSBioventus Inc.LTM Mar 2026$2.6M -979.1%-62.7%0.5%
TELATELA Bio, Inc.LTM Jun 2026$1.51M +176.9%-64.3%1.9%
Peer median (excluding BVS) $1.65M+141.0%-38.3%2.4%

Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income11.45M(144.65M)(121.2M)(318K)27.27M
Depreciation & Amortization34.88M55.4M57.37M49.56M47.01M
Deferred Income Tax(9.76M)(46.66M)(2.38M)(5.39M)(909K)
Stock-Based Compensation19.84M17.59M2.72M10.06M12.67M
Change in Working Capital(15.15M)(29.73M)(3.18M)(11.78M)(13.84M)
Accounts Receivables(20.05M)(17.67M)10.06M(10.67M)(916K)
Inventory3.18M(18.62M)(5.99M)(16.44M)8.57M
Accounts Payables0000(19.81M)
Other Working Capital1.72M6.56M(13.24M)15.32M(1.68M)
Other Non-Cash Items(18.28M)134.52M82.01M(3.33M)1.77M
Operating Cash Flow22.99M(13.54M)15.34M38.8M73.98M
Capital Expenditures(20.89M)(1.48M)(7.36M)(1.01M)(2.56M)
Acquisitions (Net)(262.87M)034.68M0(686K)
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(7.37M)(114.96M)(11.51M)23.97M0
Investing Cash Flow(283.76M)(116.44M)15.81M22.96M(3.25M)
Debt Repayment166.2M59.62M(23.26M)(59.58M)(42.91M)
Common Stock Issued109.41M5.82M778K2.44M2.07M
Common Stock Repurchased00000
Dividends Paid(367K)0000
Other Financing Activities(1.88M)(3.37M)(4.17M)2.56M(20.61M)
Financing Cash Flow273.37M62.08M(26.65M)(54.58M)(61.44M)
Effect of Forex Changes(228K)521K629K(2.56M)371K
Net Change in Cash12.37M(67.38M)5.13M4.62M9.66M
Free Cash Flow2.1M(15.02M)7.98M37.79M71.41M

Bioventus Inc.

NASDAQ:BVS

Intrinsic Alpha fair value

Locked

Current Price

$10.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.